We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Beneficial Effects of 6-Month Supplementation with Omega-3 Acids on Selected Inflammatory Markers in Patients with Chronic Kidney Disease Stages 1–3.
- Authors
Pluta, Agnieszka; Stróżecki, Paweł; Kęsy, Jacek; Lis, Kinga; Sulikowska, Beata; Odrowąż-Sypniewska, Grażyna; Manitius, Jacek
- Abstract
Introduction. Chronic kidney disease (CKD) is accompanied by inflammation. The aim of this study was to evaluate the effect of 6-month supplementation with omega-3 acids on selected markers of inflammation in patients with CKD stages 1–3. Methods. Six-month supplementation with omega-3 acids (2 g/day) was administered to 87 CKD patients and to 27 healthy individuals. At baseline and after follow-up, blood was taken for C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1) concentration and white blood cell (WBC) count. Serum concentration of omega-3 acids—eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA)—was determined using gas chromatography. And 24-hour urinary collection was performed to measure MCP-1 excretion. Results. After six-month omega-3 supplementation, ALA concentration increased in CKD patients and in the reference group, while EPA and DHA did not change. At follow-up, a significant decrease in urinary MCP-1 excretion in CKD (p=0.0012) and in the reference group (p=0.001) was found. CRP, serum MCP-1, and WBC did not change significantly. The estimated glomerular filtration rate (eGFR) did not change significantly in the CKD group. Conclusions. The reduction of urinary MCP-1 excretion in the absence of MCP-1 serum concentration may suggest a beneficial effect of omega-3 supplementation on tubular MCP-1 production. Trial Registration. This study was registered in ClinicalTrials.gov (identifier: <ext-link>NCT02147002</ext-link>).
- Subjects
ANALYSIS of variance; BLOOD testing; BLOOD cells; C-reactive protein; CHRONIC kidney failure; DIETARY supplements; GAS chromatography; PATIENT aftercare; INFLAMMATORY mediators; LYMPHOCYTES; MEDICAL needs assessment; OMEGA-3 fatty acids; URINALYSIS; LINOLEIC acid; DOCOSAHEXAENOIC acid; EICOSAPENTAENOIC acid; CONTROL groups; TREATMENT duration; DATA analysis software; DESCRIPTIVE statistics; DIAGNOSIS
- Publication
BioMed Research International, 2017, Vol 2017, p1
- ISSN
2314-6133
- Publication type
Article
- DOI
10.1155/2017/1680985